Lessons learned from the implementation of non-invasive fetal RHD screening

References

• de Haas M, Thurik FF, Koelewijn JM, et al. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109:99–113.
   PubMed Web of Science ®Google Scholar
• Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 2000;14:44–61.
   PubMed Web of Science ®Google Scholar
• Daniels G. The molecular genetics of blood group polymorphism. Hum Genet. 2009;126:729–742.
   PubMed Web of Science ®Google Scholar
• Urbaniak SJ. The scientific basis of antenatal prophylaxis. BJOG. 1998;105(Suppl.18):11–18.
   Google Scholar
• Hirose TG, Mays DA. The safety of RhIG in the prevention of haemolytic disease of the newborn. J Obstet Gynaecol. 2007;27:545–557.
   PubMedGoogle Scholar
• Liumbruno GM, D’Alessandro A, Rea F, et al. The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus. 2010;8:8–16.
   PubMed Web of Science ®Google Scholar
• Bowman JM, Chown B, Lewis M, et al. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J. 1978;118:623–627.
   PubMed Web of Science ®Google Scholar
• Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks’-gestation service program. Can Med Assoc J. 1978;118:627–630.
   PubMed Web of Science ®Google Scholar
• Crowther CA, Keirse MJ. Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database Syst Rev. 2000;2:CD000020.
   PubMedGoogle Scholar
• Turner RM, Lloyd-Jones M, Anumba DO, et al. Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS One. 2012;7:e30711.
   PubMed Web of Science ®Google Scholar
• Koelewijn JM, de Haas M, Vrijkotte TG, et al. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion. 2008;48:1721–1729.
   PubMed Web of Science ®Google Scholar
• Tiblad E, Taune Wikman A, Ajne G, et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation - outcome of a new antenatal screening and prevention program. PLoS One. 2013;8:e70984.
   PubMed Web of Science ®Google Scholar
• de Haas M, Finning K, Massey E, et al. Anti-D prophylaxis: past, present and future. Transfus Med. 2014;24:1–7.
   PubMed Web of Science ®Google Scholar
• Daniels G. Human blood groups. 3rd ed. Oxford: Wiley-Blackwell; 2013.
   Google Scholar
• Clausen FB, Damkjær MB, Dziegiel MH. Noninvasive fetal RhD genotyping. Transfussion Apher Sci. 2014;50:154–162.
   PubMed Web of Science ®Google Scholar
• Zhu YJ, Zheng YR, Li L, et al. Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis. J Matern Fetal Neonatal Med. 2014;27:1839–1844.
   PubMed Web of Science ®Google Scholar
• van der Schoot CE, Tax GH, Rijnders RJ, et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev. 2003;17:31–44.
   PubMed Web of Science ®Google Scholar
• Müller SP, Bartels I, Stein W, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion. 2008;48:2292–2301.
   PubMed Web of Science ®Google Scholar
• Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ. 2008;336:816–818.
   PubMed Web of Science ®Google Scholar
• Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion. 2012;52:752–758.
   PubMed Web of Science ®Google Scholar
• Wikman AT, Tiblad E, Karlsson A, et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol. 2012;120:227–234.
   PubMed Web of Science ®Google Scholar
• Clausen FB, Steffensen R, Christiansen M, et al. Routine noninvasive prenatal screening for fetal RHD in plasma of RhD negative pregnant women-2 years of screening experience from Denmark. Prenat Diagn. 2014;34:1000–1005.
   PubMed Web of Science ®Google Scholar
• Chitty LS, Finning K, Wade A, et al. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ. 2014;349:g5243:1–7.
   PubMedGoogle Scholar
• Soothill P, Finning K, Latham T, et al. Use of cffDNA to avoid administration of anti-D to pregnant women. when the fetus is RhD negative: implementation in the NHS. BJOG. 2015;122(12):1682–1686.
   PubMed Web of Science ®Google Scholar
• Moise KJ, Gandhi M, Boring NH, et al. Circulating cell-free DNA to determine the fetal RHD status in all three trimesters of pregnancy. Obstet Gynecol. 2016;128:1340–1346.
   PubMed Web of Science ®Google Scholar
• de Haas M, Thurik FF, van der Ploeg CP, et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. BMJ. 2016;355(i5789):1–8.
   Google Scholar
• Vivanti A, Benachi A, Huchet FX, et al. Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy. Am J Obstet Gynecol. 2016;215:606.e1–606.e5.
   PubMed Web of Science ®Google Scholar
• Haimila K, Sulin K, Kuosmanen M, et al. Targeted antenatal anti-D prophylaxis program for RhD negative pregnant women - outcome of the first two years of a national program in Finland. Acta Obstet Gynecol Scand. 2017;96:1228–1233.
   PubMed Web of Science ®Google Scholar
• Bills VL, Soothill PW. Fetal blood grouping using cell free DNA - an improved service for RhD negative pregnant women. Transfus Apher Sci. 2014;50:148¬–153.
   PubMed Web of Science ®Google Scholar
• Kent J, Farrell A-M, Soothill P. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. BMC Pregnancy and Childbirth. 2014;14(87):1–4.
   PubMedGoogle Scholar
• van der Schoot CE, de Haas M, Clausen FB. Genotyping to prevent Rh disease: has the time come? Curr Opin Hematol. 2017;24:544–550.
   PubMed Web of Science ®Google Scholar
• Westhoff CM. The structure and function of the Rh antigen complex. Semin Hematol. 2007;44:42–50.
   PubMed Web of Science ®Google Scholar
• Daniels G, Finning K, Martin P, et al. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang. 2004;87:225–232.
   PubMed Web of Science ®Google Scholar
• Daniels G. Variants of RhD – current testing and clinical consequences. Br J Haematol. 2013;161:461–470.
   PubMed Web of Science ®Google Scholar
• Stegmann TC, Veldhuisen B, Bijman R, et al. Frequency and characterization of known and novel RHD variant alleles in 37 782 Dutch D-negative pregnant women. Br J Haematol. 2016;173:469–479.
   PubMed Web of Science ®Google Scholar
• Wagner FF. RHD PCR of D-negative blood donors. Transfus Med Hemother. 2013;40:172–181.
   PubMed Web of Science ®Google Scholar
• Daniels G, Green C, Smart E. Differences between RhD negative Africans and RhD-negative Europeans. The Lancet. 1997;350:862–863.
   PubMed Web of Science ®Google Scholar
• Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype. Blood. 2000;95:12–18.
   PubMed Web of Science ®Google Scholar
• van Sandt VS, Gassner C, Emonds MP, et al. RHD variants in Flanders, Belgium. Transfusion. 2015;55(6 Pt 2):1411–1417.
   PubMed Web of Science ®Google Scholar
• Flegel WA, Denomme GA, Yazer MH. On the complexity of D antigen typing: a handy decision tree in the age of molecular blood group diagnostics. J Obstet Gynaecol Can. 2007;29:746–752.
   PubMedGoogle Scholar
• Sandler SG, Queenan JTA. Guide to terminology for Rh immunoprophylaxis. Obstet Gynecol. 2017;130:633–635.
   PubMed Web of Science ®Google Scholar
• Daniels G, Finning K, Martin P, et al. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn. 2009;29:101–107.
   PubMed Web of Science ®Google Scholar
• Maddocks DG, Alberry MS, Attilakos G, et al. The SAFE project: towards non-invasive prenatal diagnosis. Biochem Soc Trans. 2009;37(Pt 2):460–465.
   PubMedGoogle Scholar
• Grill S, Banzola I, Li Y, et al. High throughput non-invasive determination of foetal Rhesus D status using automated extraction of cell-free foetal DNA in maternal plasma and mass spectrometry. Arch Gynecol Obstet. 2009;279:533–537.
   PubMed Web of Science ®Google Scholar
• Doescher A, Petershofen EK, Wagner FF, et al. Evaluation of single-nucleotide polymorphisms as internal controls in prenatal diagnosis of fetal blood groups. Transfusion. 2013;53:353–362.
   PubMed Web of Science ®Google Scholar
• Svobodová I, Pazourková E, Hořínek A, et al. Performance of droplet digital PCR in non-invasive fetal RHD genotyping – comparison with a routine real-time PCR based approach. PLoS One. 2015;10:e0142572.
   PubMed Web of Science ®Google Scholar
• Sillence KA, Roberts LA, Hollands HJ, et al. Fetal sex and RHD genotyping with digital PCR demonstrates greater sensitivity than real-time PCR. Clin Chem. 2015;61:1399–1407.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Jeronis S, Hoffman B, et al. First trimester noninvasive fetal RHD genotyping using maternal dried blood spots. Prenat Diagn. 2017;37:311–317.
   PubMed Web of Science ®Google Scholar
• Daniels G, Finning K, Lozano M, et al. Vox Sanguinis International Forum on application of fetal blood grouping: summary. Vox Sang. 2017 Dec 28. 113:198–201. doi:10.1111/vox.12616. PMID 29282745.
   PubMed Web of Science ®Google Scholar
• Wagner FF, Flegel WA. Review: the molecular basis of the Rh blood group phenotypes. Immunohematology. 2004;20:23–36.
   PubMedGoogle Scholar
• Hyland CA, Gardener GJ, Davies H, et al. Evaluation of non-invasive prenatal RHD genotyping of the fetus. Med J Aust. 2009;191:21–25.
   PubMed Web of Science ®Google Scholar
• Grootkerk-Tax MGHM, Soussan AA, de Haas M, et al. Evalution of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion. 2006;46:2142–2148.
   PubMed Web of Science ®Google Scholar
• Hyland CA, Millard GM, O’Brien H, et al. Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: comparative accuracy using two blood collection tube types. Pathology. 2017;49:757–764.
   PubMed Web of Science ®Google Scholar
• Clausen FB, Krog GR, Rieneck K, et al. Evaluation of two real-time multiplex PCR screening assays detecting fetal RHD in plasma from RhD negative women to ascertain the requirement for antenatal RhD prophylaxis. Fetal Diagn Ther. 2011;29:155–163.
   PubMed Web of Science ®Google Scholar
• Boggione CT, Luján Brajovich ME, Mattaloni SM, et al. Genotyping approach for non-invasive foetal RHD detection in an admixed population. Blood Transfus. 2017;15:66–73.
   PubMed Web of Science ®Google Scholar
• Brajovich ME, Boggione CT, Biondi CS, et al. Comprehensive analysis of RHD alleles in Argentineans with variant D phenotypes. Transfusion. 2012;52:389–396.
   PubMed Web of Science ®Google Scholar
• Trucco Boggione C, Luján Brajovich ME, Tarragó M, et al. Molecular structures identified in serologically D- samples of an admixed population. Transfusion. 2014;54:2456–2462.
   PubMed Web of Science ®Google Scholar
• Amaral DR, Credidio DC, Pellegrino J, et al. Fetal RHD genotyping by analysis of maternal plasma in a mixed population. J Clin Lab Anal. 2011;25:100–104.
   PubMed Web of Science ®Google Scholar
• Mota M, Dezan M, Valgueiro MC, et al. RHD allelic identification among D-Brazilian blood donors as a routine test using pools of DNA. J Clin Lab Anal. 2012;26:104–108.
   PubMed Web of Science ®Google Scholar
• Martin FO, de Menezes SS, Chiba AK, et al. RHD gene polymorphisms in alloimmunized RhD-negative individuals with high rate of racial admixture. Transfus Apher Sci. 2013;48:113–116.
   PubMed Web of Science ®Google Scholar
• Schmidt LC, Cabral AC, Faria MA, et al. Noninvasive fetal RHD genotyping from maternal plasma in an admixed Brazilian population. Genet Mol Res. 2014;13:799–805.
   PubMed Web of Science ®Google Scholar
• Ziza KC, Liao AW, Dezan M, et al. Determination of fetal RHD genotype including the RHD pseudogene in maternal plasma. J Clin Lab Anal. 2017;31:e22052:1–6.
   PubMed Web of Science ®Google Scholar
• Wang XD, Wang BL, Ye SL, et al. Non-invasive foetal RHD genotyping via real-time PCR of foetal DNA from Chinese RhD negative maternal plasma. Eur J Clin Invest. 2009;39:607–617.
   PubMed Web of Science ®Google Scholar
• Tynan JA, Angkachatchai V, Ehrich M, et al. Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RHD testing. Am J Obstet Gynecol. 2011;204:251.e1–6.
   Web of Science ®Google Scholar
• Canick JA, Palomaki GE, Kloza EM, et al. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn. 2013;33:667–674.
   PubMed Web of Science ®Google Scholar
• Wang E, Batey A, Struble C, et al. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013;33:662–666.
   PubMed Web of Science ®Google Scholar
• Finning KM, Martin PG, Soothill PW, et al. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion. 2002;42:1079–1085.
   PubMed Web of Science ®Google Scholar
• Cardo L, García BP, Alvarez FV. Non-invasive fetal RHD genotyping in the first trimester of pregnancy. Clin Chem Lab Med. 2010;48:1121–1126.
   PubMed Web of Science ®Google Scholar
• Akolekar R, Finning K, Kuppusamy R, et al. Fetal RHD genotyping in maternal plasma at 11–13 weeks of gestation. Fetal Diagn Ther. 2011;29:301–306.
   PubMed Web of Science ®Google Scholar
• Manzanares S, Entrala C, Sánchez-Gila M, et al. Noninvasive fetal RhD status determination in early pregnancy. Fetal Diagn Ther. 2014;35:7–12.
   PubMed Web of Science ®Google Scholar
• Picchiassi E, Di Renzo GC, Tarquini F, et al. Non-invasive prenatal RHD genotyping using cell-free fetal DNA from maternal plasma: an Italian experience. Transfus Med Hemother. 2015;42:22–28.
   PubMed Web of Science ®Google Scholar
• Lui YYN, Lo YMD. Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. Clin Chem Lab Med. 2002;40:962–968.
   PubMed Web of Science ®Google Scholar
• Clausen FB, Krog GR, Rieneck K, et al. Improvement in fetal DNA extraction from maternal plasma. Evaluation of the nuclisens magnetic extraction system and the QIAamp DSP Virus Kit in comparison with the QIAamp DNA Blood Mini Kit. Prenat Diagn. 2007;27:6–10.
   PubMed Web of Science ®Google Scholar
• Legler TJ, Liu Z, Mavrou A, et al. Workshop report on the extraction of foetal DNA from maternal plasma. Prenat Diagn. 2007;27:824–829.
   PubMed Web of Science ®Google Scholar
• Barrett AN, Zimmermann BG, Wang D, et al. Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS One. 2011;6:e25202.
   PubMed Web of Science ®Google Scholar
• Repiská G, Sedláčkova T, Szemes T, et al. Selection of the optimal manual method of cell free fetal DNA isolation from maternal plasma. Clin Chem Lab Med. 2012;8:1–5.
   Google Scholar
• El Messaoudi S, Rolet F, Mouliere F, et al. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222–230.
   PubMed Web of Science ®Google Scholar
• Wong D, Moturi S, Angkachatchai V, et al. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem. 2013;46:1099–1104.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Aucamp J, Pretorius PJ. Cell-free DNA: preanalytical variables. Clin Chim Acta. 2015;450:243–253.
   PubMed Web of Science ®Google Scholar
• Lo YMD, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64:218–224.
   PubMed Web of Science ®Google Scholar
• Angert RM, LeShane ES, Lo YMD, et al. Fetal cell-free plasma DNA concentrations in maternal blood are stable 24 hours after collection: analysis of first- and third-trimester samples. Clin Chem. 2003;49:195–198.
   PubMed Web of Science ®Google Scholar
• Barrett AN, Thadani HA, Laureano-Asibal C, et al. Stability of cell-free DNA from maternal plasma isolated following a single centrifugation step. Prenat Diagn. 2014;34:1283–1288.
   PubMed Web of Science ®Google Scholar
• Barra GB, Santa Rita TH, de Almeida Vasques J, et al. EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. Clin Biochem. 2015;48:976–981.
   PubMed Web of Science ®Google Scholar
• Müller SP, Bartels I, Stein W, et al. Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days. Prenat Diagn. 2011;31:1300–1304.
   PubMed Web of Science ®Google Scholar
• Clausen FB, Jakobsen TR, Rieneck K, et al. Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD. PLoS One. 2013;8(10):e76990.
   PubMed Web of Science ®Google Scholar
• Clausen FB, Urhammer E, Rieneck K, et al. How to evaluate PCR assays for the detection of low-level DNA. APMIS. 2015;123:731–739.
   PubMed Web of Science ®Google Scholar
• Scheffer PG, de Haas M, van der Schoot CE. The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma. Curr Opin Hematol. 2011;18:467–473.
   PubMed Web of Science ®Google Scholar
• Zhou L, Thorson JA, Nugent C, et al. Noninvasive prenatal RHD genotyping by real-time polymerase chain reaction using plasma from D-negative pregnant women. Am J Obstet Gynecol. 2005;193:1966–1971.
   PubMed Web of Science ®Google Scholar
• Moise KJ, Boring NH, O’Shaughnessy R, et al. Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers. Prenat Diagn. 2013;33:95–101.
   PubMed Web of Science ®Google Scholar
• Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of nonin-vasive prenatal diagnosis. Clin Chem. 2006;52:2211–2218.
   PubMed Web of Science ®Google Scholar
• Li Y, Kazzaz JA, Kellner LH, et al. Incorporation of fetal DNA detection assay in a noninvasive RhD diagnostic test. Prenat Diagn. 2010;30:1010–1012.
   PubMed Web of Science ®Google Scholar
• Zejskova L, Jancuskova T, Kotlabova K, et al. Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma–next step toward reliable non-invasive prenatal diagnostics. Exp Mol Pathol. 2010;89:241–247.
   PubMed Web of Science ®Google Scholar
• Kolialexi A, Tounta G, Apostolou P, et al. Early non-invasive detection of fetal Y chromosome sequences in maternal plasma using multiplex PCR. Eur J Obstet Gynecol Reprod Biol. 2012;161:34–37.
   PubMed Web of Science ®Google Scholar
• White HE, Dent CL, Hall VJ, et al. Evaluation of a novel assay for detection of the fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive prenatal diagnosis. PLoS One. 2012;7:e45073.
   PubMed Web of Science ®Google Scholar
• Daniels G, Finning K, Lozano M, et al. Vox Sanguinis International Forum on application of fetal blood grouping. Vox Sang. 2017 Dec 28. 113:e26–e35. doi:10.1111/vox.12615. PMID 29282741.
   PubMed Web of Science ®Google Scholar
• High-throughput non-invasive prenatal testing for fetal RHD genotype. Diagnostics guidance [DG25] Nov 2016. National Institute for Health and Care Excellence (NICE). ISBN: 978-1-4731-2156-0.
   Google Scholar
• Johnson JA, MacDonald K, Clarke G, et al. No. 343-Routine non-invasive prenatal prediction of fetal RHD genotype in Canada: the time is here. J Obstet Gynaecol Can. 2017;39:366–373.
   PubMedGoogle Scholar
• Dziegiel MH. Noninvasive prenatal screening for RHD: the 1st national antenatal directed anti-D prophylaxis program – the Danish model or a guide to robust prediction of need of anti-D. ISBT Science Series. 2012;7:160–163.
   Google Scholar
• Javadi A, Veldhuisen B, de Haas M, et al. Evaluation of phocine herpesvirus (phhv) as an internal control for prenatal rhd genotyping in maternal plasma. Vox Sang. 2016;111(Suppl.1):246. [Abstract].
   Google Scholar
• Neovius M, Tiblad E, Westgren M, et al. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD negative pregnant women: a model-based analysis. BJOG. 2016;123:1337–1346.
   PubMed Web of Science ®Google Scholar
• Kacker S, Vassallo R, Keller MA, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion. 2015;55:2095–2103.
   PubMed Web of Science ®Google Scholar
• Thurik FF, Ait Soussan A, Bossers B, et al. Analysis of false-positive results of fetal RHD typing in a national screening program reveals vanishing twins as potential cause for discrepancy. Prenat Diagn. 2015;35:754–760.
   PubMed Web of Science ®Google Scholar
• Masala M, Saba L, Zoppi MA, et al. Pitfalls in noninvasive fetal RhD and sex determination due to a vanishing twin. Prenat Diagn. 2015;35:506–508.
   PubMed Web of Science ®Google Scholar
• Thurik FF, Page-Christiaens GC, Ait Soussan A, et al. Fetal RHD genotyping after bone marrow transplantation. Transfusion. 2016;56:2122–2126.
   PubMed Web of Science ®Google Scholar
• Oxenford K, Silcock C, Hill M, et al. Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women. Prenat Diagn. 2013;33:688–694.
   PubMed Web of Science ®Google Scholar
• Ma KK, Rodriguez MI, Cheng YW, et al. Should cell-free DNA testing be used to target antenatal rhesus immune globulin administration? J Matern Fetal Neonatal Med. 2016;29:1866–1870.
   PubMed Web of Science ®Google Scholar
• Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth. 2011;11:5.
   PubMed Web of Science ®Google Scholar
• Benachi A, Delahaye S, Leticee N, et al. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur J Obstet Gynecol Reprod Biol. 2012;162:28–32.
   PubMed Web of Science ®Google Scholar
• Hawk AF, Chang EY, Shields SM, et al. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol. 2013;122:579–585.
   PubMedGoogle Scholar
• Legler TJ, Müller SP, Haverkamp A, et al. Prenatal RhD testing: a review of studies published from 2006 to 2008. Transfus Med Hemother. 2009;36:189–198.
   PubMed Web of Science ®Google Scholar
• Damkjaer MB, Perslev A, Clausen FB, et al. Study of compliance with a new, targeted antenatal D immunization prevention programme in Denmark. Vox Sang. 2012;103:145–149.
   PubMed Web of Science ®Google Scholar
• Koby L, Grunbaum A, Benjamin A, et al. Anti-D in Rh(D)-negative pregnant women: are at-risk pregnancies and deliveries receiving appropriate prophylaxis? J Obstet Gynaecol Can. 2012;34:429–435.
   PubMedGoogle Scholar
• Gordon LG, Hyland CA, Hyett JA, et al. Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: a cost-effectiveness analysis. Prenat Diagn. 2017;37:1245–1253.
   PubMed Web of Science ®Google Scholar
• Teitelbaum L, Metcalfe A, Clarke G, et al. Costs and benefits of non-invasive fetal RhD determination. Ultrasound Obstet Gynecol. 2015;45:84–88.
   PubMed Web of Science ®Google Scholar
• Goodspeed TA, Allyse M, Sayres LC, et al. Translating cell-free fetal DNA technology: structural lessons from non-invasive RhD blood typing. Trends Biotechnol. 2013;31:7–9.
   PubMed Web of Science ®Google Scholar
• Daniels G, van der Schoot CE, Olsson ML. Report of the fourth International Workshop on molecular blood group genotyping. Vox Sang. 2011;101:327–332.
   PubMed Web of Science ®Google Scholar
• Clausen FB, Barrett AN, Krog GR, et al. Non-invasive foetal RhD genotyping to guide anti-D prophylaxis: an external quality assurance workshop. Blood Transfus. 2017 Apr;5:1–5. [ Epub ahead of print].
   Google Scholar
• Rieneck K, Clausen FB, Dziegiel MH. Noninvasive antenatal determination of fetal blood group using next-generation sequencing. Cold Spring Harb Perspect Med. 2015;6(1):a023093.
   PubMed Web of Science ®Google Scholar
• Wienzek-Lischka S, Krautwurst A, Fröhner V, et al. Noninvasive fetal genotyping of human platelet antigen-1a using targeted massively parallel sequencing. Transfusion. 2015;55(6 Pt 2):1538–1544.
   PubMed Web of Science ®Google Scholar
• Kjaer M, Kjeldsen-Kragh J, Fiskum C, et al. Screening for fetal and neonatal alloimmune thrombocytopenia - lessons learned from a Norwegian screening program. Acta Obstet Gynecol Scand. 2018 Feb 7. doi: 10.1111/aogs.13320. [ Epub ahead of print].
   Google Scholar